

Approved



**Ukraine**  
**Country Operational Plan**  
**FY 2016**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		212,000		212,000	0	212,000
USAID		19,361,878	2,500,000	21,861,878	957,253	22,819,131
DOD		0		0	210,000	210,000
PC		81,288		81,288	337,000	418,288
HHS/CDC	484,584	9,884,885		10,369,469	2,080,000	12,449,469
HHS/HRSA		300,000		300,000	1,200,000	1,500,000
<b>Total</b>	<b>484,584</b>	<b>29,840,051</b>	<b>2,500,000</b>	<b>32,824,635</b>	<b>4,784,253</b>	<b>37,608,888</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/EUR	USAID		
HBHC			10,000				381,142	0	391,142
HKID			114,000		81,288			0	195,288
HLAB			1,152,734			0	1,600,000	0	2,752,734
HMBL		0	3,296					0	3,296
HTXD							8,800,000	0	8,800,000
HTXS			2,609,210	300,000			266,146	0	3,175,356
HVCT		0	1,520,184				1,451,613	0	2,971,797
HVMS	143,000	0	1,520,610		0		1,065,533	0	2,729,143
HVOP		0			0		7,493	0	7,493
HVSI			2,399,885				1,641,314	0	4,041,199
HVTB			26,366				680,233	0	706,599

Approved



IDUP			90,000				265,082	0	<b>355,082</b>
OHSS		0	923,184				5,703,322	0	<b>6,626,506</b>
	<b>143,000</b>	<b>0</b>	<b>10,369,469</b>	<b>300,000</b>	<b>81,288</b>	<b>0</b>	<b>21,861,878</b>	<b>0</b>	<b>32,755,635</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	375,259	0
HKID	195,288	0
HVTB	630,276	0
<b>Total Technical Area Planned Funding:</b>	<b>1,200,823</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	2,700,000	0
HVSI	3,578,868	0
OHSS	6,360,056	0
<b>Total Technical Area Planned Funding:</b>	<b>12,638,924</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HMBL	0	0
HVCT	2,958,613	0
HVOP	0	
IDUP	355,082	0
<b>Total Technical Area Planned Funding:</b>	<b>3,313,695</b>	<b>0</b>

#### Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
-------------	----------------------------	----------------

Approved



HTXD	8,800,000	0
HTXS	2,632,629	0
<b>Total Technical Area Planned Funding:</b>	<b>11,432,629</b>	<b>0</b>



### Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0
	Number of new ANC and L&D clients	0
	By: Known positives at entry	0
	By: Number of new positives identified	0
	Sum of Positives Status disaggregates	0
	Required only for DREAMS countries - By known positives: <15	0
	Required only for DREAMS countries - By known positives: 15-19	0
	Required only for DREAMS countries - By known positives: 20-24	0
	Required only for DREAMS countries - By new positives: <15	0
	Required only for DREAMS countries - By new positives: 15-19	0
	Required only for DREAMS countries - By new positives: 20-24	0



	Required only for DREAMS countries - Denominator: <15	0
	Required only for DREAMS countries - Denominator: 15-19	0
	Required only for DREAMS countries - Denominator: 20-24	0
	Required only for DREAMS countries - Denominator: 25-49	0
	Required only for DREAMS countries - Denominator: 50+	0
	Required only for DREAMS countries - By known positives: 25-49	0
	Required only for DREAMS countries - By known positives: 50+	0
	Required only for DREAMS countries - By new positives: 25-49	0
	Required only for DREAMS countries - By new positives: 50+	0
	By Age (DREAMS SNUs ONLY): <15	0
	By Age (DREAMS SNUs ONLY): 15-19	0
	By Age (DREAMS SNUs ONLY): 20-24	0
	By Age (DREAMS SNUs ONLY): 25-49	0
	By Age (DREAMS SNUs ONLY): 50+	0
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs	500



	(PWID) on medication assisted therapy (MAT) for at least 6 months	
	Sex: Male	350
	Sex: Female	150
	Sum of Sex disaggregates	500
KP_MAT_TA	KP_MAT_TA Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	2,525
	Sex: Female	577
	Sex: Male	1,948
	Sum of Sex Disaggregates	2,525
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have received antiretroviral preexposure	100
	Male 10-14	
	Male 15-19	
	Male 20-24	60
	Male 25-49	40
	Male 50+	
	Female 10-14	
	Female 15-19	
	Female 20-24	
	Female 25-49	
	Female 50+	
	PP_PREV_DSD	PP_PREV_DSD Percentage of the



	target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,752
	Total number of people in the target population	103,600
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	



	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	1,732
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	1,020
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	34,286
	Total estimated number of key population in the catchment area	225,700
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	



	<p>By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>3,146</p>
	<p>By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual</p>	<p>21,797</p>



	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9,343
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	41,300
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type:	



	Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	125,392
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	59,008
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturning beneficiary within the current report period	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received	87,035



	their test results during the past 12 months	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex:	



	Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	40
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	54,041
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	40
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	32,914
	Test Result by Aggregated Age	



	and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	7
	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,445
	Test Result by Aggregated Age and Sex: Positive <15 Female	2
	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,184
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community)	



	by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	0
	Service Delivery Point (Facility): Outpatient	59,835
	Service Delivery Point (Facility): Pediatric	0
	Service Delivery Point (Facility): Malnutrition facilities	0
	Service Delivery Point (Facility): Other PITC	1,200
	Service Delivery Point (Facility): VCT	25,000
	Service Delivery Point (Facility): VMMC	0
	Service Delivery Point (Facility): PMTCT	0
	Service Delivery Point (Facility): TB Clinics	0
	Service Delivery Point (Facility): Index testing	1,000
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by	



	Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by	



	Age: >15 Index testing	
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,488
	Total number of registered new and relapsed TB cases, during the reporting period.	5,586
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	14
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,743
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,723
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB)	



	cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs	



	for children and families affected by HIV/AIDS	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	
	Sum of Age/Sex disaggregates	
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and	



	sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and	



	sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and	



	sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening	



	Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and	



	sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and	



	sex: Other Services Male 1-9	
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	99
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	121
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	350



	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-9 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By age/sex: 18-24 Male	
	By age/sex: 25+ Male	
	Age/Sex: 18+ Male	11
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-9 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By age/sex: 18-24 Female	
	By age/sex: 25+ Female	
	Age/Sex: 18+ Female	119
	Sum of Age/Sex disaggregates	130
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14	



	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male	



	18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+	
	Required only for DREAMS countries: By Service Area, age	



	and sex: Parenting/Caregiver Program Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4	
	Required only for DREAMS	



	countries: By Service Area, age and sex: Social Protection Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male	



	15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries: By Service Area, age	



	and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1	
	Required only for DREAMS	



	countries: By Service Area, age and sex: Other Service Areas Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection 1-9	



	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas <1	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 25+	
	By Aggregated Age/Sex: <18 Male	
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Program	



	1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Other Service Areas 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Social Protection 1-9 Female	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas 1-9	
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	0
	By infants who received their first virologic HIV test between 2 and 12 months of age	0
	Sum of Infant Age disaggregates	0
	By infants with a positive virologic test result within 12 months of birth	



	Number of infants with a positive virological test result within 2 months of birth	0
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	38,766
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 15+ Male	21,325
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	17,448
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	38,773
	Sum of Aggregated Age/Sex disaggregates	38,773
Age/Sex: <1		
Age/Sex: <1-9		



	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	20,786
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	



	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	11,432
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	9,364
	Sum of Aggregated Age/Sex disaggregates	20,796
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	25,833
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	33,095
	Numerator: Indication: Routine	25,830



	Numerator: Indication: Targeted	0
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication:	



	<1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by	



	Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	33,003
	Denominator: Indication: Targeted	0
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by	



	Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex	



	by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	14,197
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	11,632
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	18,206
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	14,895
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	15,321



	<p>Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up</p>	<p>18,046</p>
	<p>Age/Sex: &lt;1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>	
	<p>Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>	
	<p>Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>	
	<p>Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>	
	<p>Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>	
	<p>Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>	
	<p>Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>	



	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have	



	died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children	



	who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status:	



	Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,423
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,900
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated	9,912



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,133
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	224,960
	Number of HIV Test Kits purchased	93,140
	Number of HIV CD4 Reagents purchased	37,790
	Number of Condoms purchased	5,000
	Number of HIV Viral Load Reagents purchased	54,625
	Number of HIV ARVs purchased	39,505
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned	109,797

Approved



	(COP)/ spent (Actual)	
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	509,610
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	914,475
	Condoms: Dollars planned (COP)/ spent (Actual)	25,000
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	8,991,928



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7520	International HIV/AIDS TB Institute	NGO	U.S. Department of Defense	GHP-State	0
12845	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	170,699
12899	Pact	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	3,652,586
12957	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
13168	American Society for Microbiology	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
13232	Deloitte Consulting Limited	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	3,100,000
13252	World Health Organization	Multi-lateral Agency	U.S. Department of Health and	GHP-State	660,000



			Human Services/Centers for Disease Control and Prevention		
13268	American Society of Clinical Pathology	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	350,000
13582	UNODC	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	0
14071	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	81,288
14219	American International Health Alliance	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14225	Program for Appropriate Technology in Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14235	International HIV/AIDS Alliance	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	2,921,000



			Control and Prevention		
14240	World Health Organization	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	0
14247	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	0
14254	All Ukrainian Network of People Living with HIV/AIDS	NGO	U.S. Agency for International Development	GHP-State	550,498
14255	All Ukrainian Network of People Living with HIV/AIDS	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	700,000
16718	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	400,000
17331	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	150,000
17332	Regional Procurement Support	Other USG Agency	U.S. Department of State/Bureau of European and	GHP-State	0



	Office/Frankfurt		Eurasian Affairs		
17345	International HIV/AIDS Alliance	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
17922	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	400,000
17932	Ministry of Health (MOH)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17938	TBD	TBD	Redacted	Redacted	Redacted
18210	TBD	TBD	Redacted	Redacted	Redacted
18211	TBD	TBD	Redacted	Redacted	Redacted
18212	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development	GHP-State	350,000
18219	TBD	TBD	Redacted	Redacted	Redacted
18449	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	0
18451	International Center for AIDS Care and Treatment Programs,	University	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	400,000

Approved



	Columbia University		Control and Prevention		
18452	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	10,400,000
18453	New Partner	TBD	U.S. Agency for International Development	GHP-State	0



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 7520</b>	<b>Mechanism Name: Prevention for the Military</b>
Funding Agency: DOD	Procurement Type: Contract
Prime Partner Name: International HIV/AIDS TB Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 100,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 7520</b>			
<b>Mechanism Name: Prevention for the Military</b>			
<b>Prime Partner Name: International HIV/AIDS TB Institute</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0
PMTCT_STAT_TA	Number of new ANC and L&D clients	0
PMTCT_STAT_TA	By: Known positives at entry	0
PMTCT_STAT_TA	By: Number of new positives identified	0
PMTCT_STAT_TA	Sum of Positives Status disaggregates	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	0
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 15-19	0
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 20-24	0
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator:	0



	25-49	
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 50+	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 50+	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 25-49	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 50+	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): <15	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 15-19	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 20-24	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 25-49	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 50+	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	25,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	22,500
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,500
HTC_TST_TA	Sum of Aggregated Age/Sex <15	0
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	25,000
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	25,000
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	500



HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	10
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	0
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	0
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	0
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	0
HTC_TST_TA	Service Delivery Point (Facility): VCT	25,000
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	0
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	0
HTC_TST_TA	Service Delivery Point (Facility): Index testing	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	0
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	0
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	0
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	0



PMTCT_EID_TA	Sum of Infant Age disaggregates	0
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0

### Implementing Mechanism Details

<b>Mechanism ID: 12845</b>	<b>Mechanism Name: Strengthening TB Control in Ukraine</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 170,699</b>	
<b>Applied Pipeline Amount: 279,301</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 450,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	170,699

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	150,699
Gender: Gender Equality	10,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Capacity building

### Budget Code Information



<b>Mechanism ID:</b> 12845			
<b>Mechanism Name:</b> Strengthening TB Control in Ukraine			
<b>Prime Partner Name:</b> Chemonics International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	170,699	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,000
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	5,098
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,393
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,607

### Implementing Mechanism Details

<b>Mechanism ID: 12899</b>	<b>Mechanism Name: RESPOND -- Comprehensive KPs</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pact	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,652,586</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,652,586</b>	



Funding Source	Funding Amount
GHP-State	3,652,586

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	200,000
Key Populations: MSM and TG	80,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Gender: Gender Equality	10,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Capacity building
Gender: GBV	10,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information

**Budget Code Information**

<b>Mechanism ID:</b>	12899		
<b>Mechanism Name:</b>	RESPOND -- Comprehensive KPs		
<b>Prime Partner Name:</b>	Pact		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	365,259	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	109,577	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	438,310	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	1,387,983	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	1,168,828	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	182,629	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,752
PP_PREV_DSD	Total number of people in the target population	103,600
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	1,732
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	1,020
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,146
KP_PREV_DSD	Total estimated number of key population in the catchment area	41,300
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,146



KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	41,300
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	59,835
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	40
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	29,879
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	40
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	29,876
HTC_TST_TA	Sum of Aggregated Age/Sex <15	80
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	59,755
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	59,835
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	7
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,862
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	2
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,124
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	59,835

### Implementing Mechanism Details

<b>Mechanism ID: 12957</b>	<b>Mechanism Name: APHL</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



G2G: No	Managing Agency:
---------	------------------

<b>Total All Funding Sources: 300,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	300,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	30,000
----------------------------	--------

**Budget Code Information**

<b>Mechanism ID:</b> 12957			
<b>Mechanism Name:</b> APHL			
<b>Prime Partner Name:</b> Association of Public Health Laboratories			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	300,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 13168</b>	<b>Mechanism Name: ASM</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 300,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	300,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	120,000
----------------------------	---------

**Budget Code Information**

<b>Mechanism ID:</b>	13168		
<b>Mechanism Name:</b>	ASM		
<b>Prime Partner Name:</b>	American Society for Microbiology		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	300,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 13232</b>	<b>Mechanism Name: HSS SHARe HIV Reform in Action-Removing HIV/AIDS Services" legal &amp; operational barriers</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: Deloitte Consulting Limited	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,100,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	600,000
GHP-USAID	2,500,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	300,000
Gender: Gender Equality	150,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b>	13232
<b>Mechanism Name:</b>	HSS SHARe HIV Reform in Action-Removing HIV/AIDS Services" legal & Prime Partner Name: operational barriers



Deloitte Consulting Limited			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	390,558	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	2,161,575	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	282,785	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	265,082	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 13252</b>	<b>Mechanism Name: WHO</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 660,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 660,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	660,000



**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	154,000
----------------------------	---------

**Budget Code Information**

<b>Mechanism ID:</b> 13252			
<b>Mechanism Name:</b> WHO			
<b>Prime Partner Name:</b> World Health Organization			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	660,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 13268	<b>Mechanism Name:</b> ASCP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society of Clinical Pathology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 350,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 350,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	350,000



**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	120,000
----------------------------	---------

**Budget Code Information**

<b>Mechanism ID:</b>	13268		
<b>Mechanism Name:</b>	ASCP		
<b>Prime Partner Name:</b>	American Society of Clinical Pathology		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	350,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 13582</b>	<b>Mechanism Name: HIV PLEDGE</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: UNODC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13582			
<b>Mechanism Name:</b> HIV PLEDGE			
<b>Prime Partner Name:</b> UNODC			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)



**Implementing Mechanism Details**

<b>Mechanism ID: 14071</b>	<b>Mechanism Name: Peace Corps Responding to HIV/AIDS</b>
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 81,288</b>	
<b>Applied Pipeline Amount: 124,434</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 205,722</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	81,288

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	5,000
Economic Strengthening	20,000
Key Populations: MSM and TG	5,000
Focus Area:	Training of health workers and community outreach workers
Gender: Gender Equality	5,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Capacity building

**Budget Code Information**

<b>Mechanism ID:</b>	<b>14071</b>
----------------------	--------------



<b>Mechanism Name:</b>	Peace Corps Responding to HIV/AIDS		
<b>Prime Partner Name:</b>	U.S. Peace Corps		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	81,288	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	99
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	121
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	350
OVC_SERV_TA	Age/Sex: 18+ Male	11
OVC_SERV_TA	Age/Sex: 18+ Female	119
OVC_SERV_TA	Sum of Age/Sex disaggregates	130

### Implementing Mechanism Details

<b>Mechanism ID: 14219</b>	<b>Mechanism Name: AIHA Blood Safety Technical Assistance Services (HQ)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	14219		
<b>Mechanism Name:</b>	AIHA Blood Safety Technical Assistance Services (HQ)		
<b>Prime Partner Name:</b>	American International Health Alliance		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 14225</b>	<b>Mechanism Name: PATH</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0



## Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	14225		
<b>Mechanism Name:</b>	PATH		
<b>Prime Partner Name:</b>	Program for Appropriate Technology in Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	488
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	488
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	14
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	350
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	116



**Implementing Mechanism Details**

<b>Mechanism ID: 14235</b>	<b>Mechanism Name: ALLIANCE_ METIDA (ending) NGO Support for SI Activities</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International HIV/AIDS Alliance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,921,000</b>	
<b>Applied Pipeline Amount: 500,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,421,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,921,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1,310,500
Key Populations: FSW	250,000
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	250,000
Focus Area:	Monitoring and evaluation of MSM/TG programs

**Budget Code Information**

<b>Mechanism ID:</b>	14235		
<b>Mechanism Name:</b>	ALLIANCE_ METIDA (ending) NGO Support for SI Activities		
<b>Prime Partner Name:</b>	International HIV/AIDS Alliance		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	114,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,507,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	100
PrEP_NEW_DSD	Male 20-24	60
PrEP_NEW_DSD	Male 25-49	40
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	33,140
KP_PREV_DSD	Total estimated number of key population in the catchment area	184,400
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,000
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	21,797
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV	9,343



	preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	125,392
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	59,008
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	33,140
INVS_COMD	Number of HIV Test Kits purchased	33,140
INVS_COMD	Number of HIV ARVs purchased	100
INVS_COMD	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	34,797
INVS_COMD	HIV ARVs: Dollars planned (COP)/ spent (Actual)	10,000

### Implementing Mechanism Details

<b>Mechanism ID: 14240</b>	<b>Mechanism Name: WHO</b>
Funding Agency: USAID	Procurement Type: Umbrella Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 97,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 97,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID: 14240</b>			
<b>Mechanism Name: WHO</b>			
<b>Prime Partner Name: World Health Organization</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 14247</b>	<b>Mechanism Name: SIAPS</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID: 14247</b>			
<b>Mechanism Name: SIAPS</b>			
<b>Prime Partner Name: Management Sciences for Health</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 14254</b>	<b>Mechanism Name: Stigma and discrimination</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: All Ukrainian Network of People Living with HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 550,498</b>	
<b>Applied Pipeline Amount: 195,952</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 746,450</b>	
Funding Source	Funding Amount
GHP-State	550,498



### Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	27,525
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Human Resources for Health	110,100

### Budget Code Information

<b>Mechanism ID:</b>	14254		
<b>Mechanism Name:</b>	Stigma and discrimination		
<b>Prime Partner Name:</b>	All Ukrainian Network of People Living with HIV/AIDS		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	550,498	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,200
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,162
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	38
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	1,200
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	1,200
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+	33



	Male	
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	1,200

**Implementing Mechanism Details**

<b>Mechanism ID: 14255</b>	<b>Mechanism Name: NETWORK (ending) Support to ART provision</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: All Ukrainian Network of People Living with HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 700,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 700,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	700,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	105,000
----------------------------	---------

**Budget Code Information**

<b>Mechanism ID: 14255</b>			
<b>Mechanism Name: NETWORK (ending) Support to ART provision</b>			
<b>Prime Partner Name: All Ukrainian Network of People Living with HIV/AIDS</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	HVSI	550,000	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	150,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16718</b>	<b>Mechanism Name: UCSF</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 400,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 400,000</b>	
Funding Source	Funding Amount
GHP-State	400,000

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	80,000
----------------------------	--------



**Budget Code Information**

<b>Mechanism ID:</b> 16718			
<b>Mechanism Name:</b> UCSF			
<b>Prime Partner Name:</b> University of California at San Francisco			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	250,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17331	<b>Mechanism Name:</b> CLSI
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 150,000	
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 150,000	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	150,000

**Cross-Cutting Budget Attribution(s)**



Human Resources for Health	45,500
----------------------------	--------

**Budget Code Information**

<b>Mechanism ID: 17331</b>			
<b>Mechanism Name: CLSI</b>			
<b>Prime Partner Name: Clinical and Laboratory Standards Institute</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	150,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 17332</b>	<b>Mechanism Name: NPHC Laboratory Renovation</b>
Funding Agency: State/EUR	Procurement Type: Contract
Prime Partner Name: Regional Procurement Support Office/Frankfurt	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

Approved



(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17332			
<b>Mechanism Name:</b> NPHC Laboratory Renovation			
<b>Prime Partner Name:</b> Regional Procurement Support Office/Frankfurt			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17345	<b>Mechanism Name:</b> Alliance MAT
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International HIV/AIDS Alliance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 100,000	
<b>Applied Pipeline Amount:</b> 500,000	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 600,000	
Funding Source	Funding Amount
GHP-State	100,000

**Cross-Cutting Budget Attribution(s)**



(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17345			
<b>Mechanism Name:</b> Alliance MAT			
<b>Prime Partner Name:</b> International HIV/AIDS Alliance			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	10,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	90,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2017
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	500
KP_MAT_DSD	Sex: Male	350
KP_MAT_DSD	Sex: Female	150
KP_MAT_DSD	Sum of Sex disaggregates	500
KP_MAT_TA	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	2,525
KP_MAT_TA	Sex: Female	577
KP_MAT_TA	Sex: Male	1,948
KP_MAT_TA	Sum of Sex Disaggregates	2,525

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17922	<b>Mechanism Name:</b> MEASURE EVALUATION IV
----------------------------	--



Funding Agency: USAID	Procurement Type: Umbrella Agreement
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 400,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 400,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	400,000

**Cross-Cutting Budget Attribution(s)**

Gender: Gender Equality	10,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Human Resources for Health	100,000

**Budget Code Information**

<b>Mechanism ID:</b>	17922		
<b>Mechanism Name:</b>	MEASURE EVALUATION IV		
<b>Prime Partner Name:</b>	University of North Carolina at Chapel Hill, Carolina Population Center		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	HVSI	400,000	0

Approved



Systems			
---------	--	--	--

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17932</b>	<b>Mechanism Name: NPHC/UCDC Epi/Surv/QI</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health (MOH)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 600,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 600,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17932		
<b>Mechanism Name:</b>	NPHC/UCDC Epi/Surv/QI		
<b>Prime Partner Name:</b>	Ministry of Health (MOH)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	HVSI	0	0



Systems			
---------	--	--	--

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 17938</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18210</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18211</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18212</b>	<b>Mechanism Name: Challenge TB</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: KNCV Tuberculosis Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 350,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 350,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>



GHP-State	350,000
-----------	---------

**Cross-Cutting Budget Attribution(s)**

Gender: Gender Equality	50,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Capacity building
Human Resources for Health	150,000

**Budget Code Information**

<b>Mechanism ID:</b> 18212 <b>Mechanism Name:</b> Challenge TB <b>Prime Partner Name:</b> KNCV Tuberculosis Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	350,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 18219	<b>TBD:</b> Yes
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 18449	<b>Mechanism Name:</b> Strengthening military lab/commodities
----------------------------	---



Funding Agency: DOD	Procurement Type: Contract
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 100,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18449</b>			
<b>Mechanism Name: Strengthening military lab/commodities</b>			
<b>Prime Partner Name: U.S. Department of Defense (Defense)</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0

**Implementing Mechanism Indicator Information**

<b>Indicator Number</b>	<b>Label</b>	<b>2017</b>
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12	60,000



	months by Implementing Partner	
INVS_COMD	Number of HIV Test Kits purchased	60,000
INVS_COMD	Number of Condoms purchased	5,000
INVS_COMD	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	75,000
INVS_COMD	Condoms: Dollars planned (COP)/ spent (Actual)	25,000

**Implementing Mechanism Details**

<b>Mechanism ID: 18451</b>	<b>Mechanism Name: ICAP</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 400,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 400,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	400,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	200,000
----------------------------	---------

**Budget Code Information**

<b>Mechanism ID:</b>	18451		
<b>Mechanism Name:</b>	ICAP		
<b>Prime Partner Name:</b>	International Center for AIDS Care and Treatment Programs, Columbia University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXS	400,000	0
-----------	------	---------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18452</b>	<b>Mechanism Name: Global Health Supply Chain Program</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 10,400,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 10,400,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	10,400,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 18452</b>			
<b>Mechanism Name: Global Health Supply Chain Program</b>			
<b>Prime Partner Name: Global Health Supply Chain Program</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HLAB	1,600,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXD	8,800,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2017
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	131,820
INVS_COMD	Number of HIV CD4 Reagents purchased	37,790
INVS_COMD	Number of HIV Viral Load Reagents purchased	54,625
INVS_COMD	Number of HIV ARVs purchased	39,405
INVS_COMD	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	509,610
INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	914,475
INVS_COMD	HIV ARVs: Dollars planned (COP)/ spent (Actual)	8,981,928

**Implementing Mechanism Details**

<b>Mechanism ID: 18453</b>	<b>Mechanism Name: UCDC Commodity Reporting</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0



## Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18453		
<b>Mechanism Name:</b>	UCDC Commodity Reporting		
<b>Prime Partner Name:</b>	New Partner		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	38,766
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	21,325
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	17,448
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	38,773
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	38,773
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	20,786
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	11,432
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	9,364
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	20,796
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	25,833



TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	33,095
TX_PVLS_DSD	Numerator: Indication: Routine	25,830
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	33,003
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	14,197
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	11,632
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	18,206
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	14,895
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	15,321
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	18,046
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,423
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,900
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,912
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,133

### Agency Information - Costs of Doing Business



### U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		79,383		0	79,383	79,383
ICASS		174,195		0	174,195	174,195
Management Meetings/Professional Development		62,200		0	62,200	62,200
Non-ICASS Administrative Costs		253,966		150,000	253,966	403,966
Staff Program Travel		41,754		35,000	41,754	76,754
USG Staff Salaries and Benefits - Internationally Recruited		552,631		100,000	552,631	652,631
USG Staff Salaries and Benefits - Locally Recruited		373,966		100,000	373,966	473,966
<b>Total</b>	<b>0</b>	<b>1,538,095</b>	<b>0</b>	<b>385,000</b>	<b>1,538,095</b>	<b>1,923,095</b>



**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Staff Program Travel		0		10,000	0	10,000
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>10,000</b>	<b>0</b>	<b>10,000</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		168,000		0	168,000	168,000
Computers/IT Services		45,000		0	45,000	45,000
ICASS		65,000		240,000	65,000	305,000
Institutional Contractors				0	0	0
Management Meetings/Professional		0		70,000	0	70,000



Development						
Non-ICASS Administrative Costs		198,832		0	198,832	198,832
Staff Program Travel	0	187,600		170,000	187,600	357,600
USG Staff Salaries and Benefits - Internationally Recruited	484,584	937,185		0	1,421,769	1,421,769
USG Staff Salaries and Benefits - Locally Recruited		402,268		0	402,268	402,268
<b>Total</b>	<b>484,584</b>	<b>2,003,885</b>	<b>0</b>	<b>480,000</b>	<b>2,488,469</b>	<b>2,968,469</b>

**U.S. Department of State**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		10,000		0	10,000	10,000
ICASS		30,000		0	30,000	30,000
Management Meetings/Professional		10,000		0	10,000	10,000



Development						
Non-ICASS Administrative Costs		18,000		0	18,000	18,000
Staff Program Travel		25,000		0	25,000	25,000
USG Staff Salaries and Benefits - Internationally Recruited		69,000		0	69,000	69,000
USG Staff Salaries and Benefits - Locally Recruited		50,000		0	50,000	50,000
<b>Total</b>	<b>0</b>	<b>212,000</b>	<b>0</b>	<b>0</b>	<b>212,000</b>	<b>212,000</b>

**U.S. Peace Corps**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		0		300	0	300
Management Meetings/Professional Development		0		14,900	0	14,900

Approved



Non-ICASS Administrative Costs		0		2,224	0	2,224
Peace Corps Volunteer Costs				117,822	0	117,822
Staff Program Travel		0		10,620	0	10,620
USG Staff Salaries and Benefits - Locally Recruited		0		66,700	0	66,700
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>212,566</b>	<b>0</b>	<b>212,566</b>